53,295 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 53,295 shares of the company’s stock, valued at approximately $1,203,000.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of PROCEPT BioRobotics during the second quarter worth $109,961,000. Prosight Management LP raised its stake in PROCEPT BioRobotics by 1,692.4% in the 4th quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after acquiring an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its stake in PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after purchasing an additional 1,218,815 shares during the period. Finally, William Blair Investment Management LLC purchased a new position in shares of PROCEPT BioRobotics in the second quarter worth about $16,020,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, CEO Larry Wood purchased 23,900 shares of the company’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 1,000 shares of company stock worth $28,480 in the last ninety days. 4.00% of the stock is owned by company insiders.

PROCEPT BioRobotics Stock Up 6.5%

Shares of NASDAQ PRCT opened at $22.76 on Friday. PROCEPT BioRobotics Corporation has a 1 year low of $16.67 and a 1 year high of $41.51. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The company has a market capitalization of $1.30 billion, a P/E ratio of -11.73 and a beta of 0.91. The company has a 50 day simple moving average of $20.35 and a 200-day simple moving average of $23.69.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the company earned ($0.35) EPS. On average, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Wall Street Analyst Weigh In

PRCT has been the topic of several research reports. Piper Sandler cut their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Evercore set a $23.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Truist Financial set a $21.00 target price on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $31.00 to $29.00 in a research report on Thursday, June 11th. Finally, Citigroup lowered shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, PROCEPT BioRobotics currently has an average rating of “Hold” and an average price target of $25.09.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.